Below please find a link to Proactive Investors’ video interview with AzurRx CEO James Sapirstein on March 9, 2020.

https://www.proactiveinvestors.com/companies/news/917067/azurrx-reveals-most-recent-advancements-in-its-gastrointestinal-disorder-clinical-development-917067.html

Proactive Investors is not associated with AzurRx BioPharma, nor was Proactive Investors paid for its report.  AzurRx is not responsible for the completeness, accuracy, timeliness or omissions contained in the report, or for the results obtained from the use of the information contained in the report, which may not provide all information material to an investor’s decision whether or not to make an investment.  AzurRx is not responsible for the results obtained from the use of the information contained in the report.  Investors should carefully review AzurRx’s reports filed with the Securities and Exchange Commission (SEC) before deciding to invest, including AzurRx’s risk factors contained in its Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2019, and subsequent Quarterly Reports filed on Form 10-Q, and Current Reports filed on Form 8-K.